Osteoporosis Treatment Market Size, Analytical Overview, Growth Factors, Demand Trends And Forecast 2033

The osteoporosis treatment market size has grown strongly in recent years. It will grow from $13.16 billion in 2023 to $13.87 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to aging population demographics, hormone replacement therapies, calcium and vitamin d supplementation, increased diagnostic tools, integration of digital health solutions.

The osteoporosis treatment market size is expected to see steady growth in the next few years. It will grow to $16.6 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to rise in sedentary lifestyles, rising prevalence of secondary osteoporosis, virtual bone fracture clinics, gene therapy for osteoporosis, increased focus on men's bone health. Major trends in the forecast period include advancements in biologics, integration of artificial intelligence, blockchain in bone health records, integration of machine learning.

Market Overview -
Osteoporosis treatment refers to medical interventions aimed at managing and improving the condition of osteoporosis. Osteoporosis is a bone disease that appears when bone mass and mineral density decline or when the composition and strength of bones alter.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12166&type=smp

Rising Prevalence Of Osteoporosis Fuels Growth In Osteoporosis Treatment Market
The increasing prevalence and incidence of osteoporosis are expected to propel the growth of the osteoporosis treatment market going forward. Osteoporosis is a bone disease that manifests when bone strength and composition change or when bone mass and mineral density drop. Most osteoporosis drugs function by slowing down the rate at which your bones deteriorate. At the same time, hormone-based treatments such as estrogen can help maintain bone density, especially when taken immediately after menopause. For instance, in May 2022, according to Amgen, a US-based biopharmaceutical company, the annual number of fractures due to osteoporosis is expected to increase by 68% to 3.2 million by 2040. Therefore, the increasing prevalence and incidence of osteoporosis are driving the growth of the osteoporosis treatment market.

Competitive Landscape -
Major companies operating in the osteoporosis treatment market report are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck and Co Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline Pharmaceutical Ltd., Takeda Pharmaceutical Company, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Corporation, AstraZeneca Plc., Viatris Inc., Allergan plc, Teva Pharmaceuticals Industries Ltd., Biogen Inc., Daiichi Sankyo company Ltd, Dr. Reddy's Laboratories, Gedeon Richter Plc., Celltrion Inc., Luye Pharma Group, Covis Pharmaceuticals Inc., Ligand Pharmaceuticals Incorporated, Radius Health Inc., Haoma Medica Ltd., Actavis plc, EffRx Pharmaceuticals SA

Innovative Solutions Transform Osteoporosis Treatment Market
Product innovation is a key trend gaining popularity in the osteoporosis treatment market. Major companies operating in the osteoporosis treatment market are adopting recent technologies to sustain their position in the market. For instance, in January 2021, Theramex, a UK-based pharmaceutical company, launched Livogiva, a new teriparatide pre-filled pen for treating severe osteoporosis. Livogiva is a biosimilar of the Forsteo reference drug teriparatide, and in phase III clinical investigation, individuals with severe osteoporosis who received treatment for six months showed therapeutic equivalence.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/osteoporosis-treatment-global-market-report

Key Segments -
The osteoporosis treatment market covered in this report is segmented -
1) By Drug Type: Bisphosphonates, Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, Rank Ligand (RANKL) Inhibitor
2) By Route of Administration: Oral, Injectable, Other Routes
3) By Distribution Channel: Hospitals, Retail Pharmacies And Stores, Online Pharmacies

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.